198 related articles for article (PubMed ID: 30941996)
1. Ten-year experience with peritoneal mesothelioma.
Kyziridis D; Hristakis C; Kalakonas A; Vaikos D; Pallas N; Karamveri C; Kyriakopoulos V; Tentes AA
J BUON; 2019; 24(1):391-396. PubMed ID: 30941996
[TBL] [Abstract][Full Text] [Related]
2. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
[TBL] [Abstract][Full Text] [Related]
4. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
Gilani SNS; Mehta A; Garcia-Fadrique A; Rowaiye B; Jenei V; Dayal S; Chandrakumaran K; Carr N; Mohamed F; Cecil T; Moran B
Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
[TBL] [Abstract][Full Text] [Related]
6. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
7. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
[TBL] [Abstract][Full Text] [Related]
8. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years.
Scalabre A; Philippe-Chomette P; Passot G; Orbach D; Elias D; Corradini N; Brugières L; Msika S; Leclair MD; Joseph S; Brigand C; Becmeur F; Soler C; Pezet D; Gagniere J; Glehen O; Sarnacki S
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286576
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
[TBL] [Abstract][Full Text] [Related]
11. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
[TBL] [Abstract][Full Text] [Related]
12. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
13. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
14. Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
Chandramohan A; Thrower A; Shah N; Mohamed F
Br J Radiol; 2017 Nov; 90(1079):20170361. PubMed ID: 28830230
[TBL] [Abstract][Full Text] [Related]
15. Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.
Deraco M; Nizri E; Glehen O; Baratti D; Tuech JJ; Bereder JM; Kepenekian V; Kusamura S; Goere D
Eur J Surg Oncol; 2019 Mar; 45(3):371-375. PubMed ID: 30473172
[TBL] [Abstract][Full Text] [Related]
16. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
20. Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.
Nizri E; Baratti D; Guaglio M; Sinukumar S; Cabras A; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jul; 44(7):1100-1104. PubMed ID: 29703622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]